GW Pharmaceuticals (Nasdaq: GWPH) tremendous 700% one year run is showing no signs of slowing down. The drug developer, often lumped in with marijuana stocks due to its focus on the cannabinoid system, received an FDA fast track designation for its orphan drug Epidiolex. This drug is hoping to treat Dravet and Lennox- Gastaut syndromes, both are rare forms of pediatric epilepsy and have a significant unmet need for treatments.
Epidiolex as a wholly owned drug has significant potential for GW and could cross $500 million in global peak sales, easily supplanting its current approved drug Sativex as the company's flagship product.
In this episode of Market Checkup, the Motley Fool's health care focused investing show, analysts David Williamson and Michael Douglass discuss the recent regulatory good news, the market potential for Epidiolex and why Fools should be watching this stock closely.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need to Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.